Before or after transplantation? A review of the cost effectiveness of treating waitlisted patients with hepatitis c

Transplantation

Volumn 101, Issue 5, 2017, Pages 933-937

  Tapper, Elliot B ^a   Afdhal, Nezam H ^a   Curry, Michael P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SOFOSBUVIR; VELPATASVIR; ANTIVIRUS AGENT;

CHILD PUGH SCORE; CHRONIC HEPATITIS C; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; GRAFT FAILURE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SUSTAINED VIROLOGIC RESPONSE; COMPLICATION; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; END STAGE LIVER DISEASE; HOSPITAL ADMISSION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROCEDURES; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; END STAGE LIVER DISEASE; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; POSTOPERATIVE CARE; PREOPERATIVE CARE; UNITED STATES; WAITING LISTS;

EID: 85018233003     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001611     Document Type: Review

References (31)

1. Tapper EB HM, Buti M, Dufour JF, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: a cost-effectiveness analysis. [published online ahead of print August 4, 2016]. Transplantation. doi: 10.1097/TP.0000000000001400.
2. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370:1483-1493.
3. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl JMed. 2014;370:1889-1898.
4. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
5. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100-107. e101.
6. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485-1494.
7. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1,-2, and-3 clinical trials. Hepatology. 2015;61:1798-1808.
8. Roth D, Nelson DR, Bruchfeld A, et al.Grazoprevir plus elbasvir in treatmentnaive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. The Lancet. 2015;386:1537-1545.
9. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl JMed. 2014;371:2375-2382.
10. Younossi ZM, Boparai N, McCormick M, et al. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol. 2001;96:579-583.
11. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-2593.
12. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015; 373:2618-2628.
13. Veldt BJ, Heathcote EJ,Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.
14. Asrani SK, O'Leary JG. The changing liver transplant waitlist: an emerging liver purgatory? Gastroenterology. 2015;3:493-496.
15. Reig M, Mariño Z, Perelló C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;65: 719-726.
16. Yang JD, Aqel BA, Pungpapong S, et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016;65:859-860.
17. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the 50,000-per-QALY threshold. N Engl JMed. 2014;371:796-797.
18. Cheung MC, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741-747.
19. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon ?-2b plus ribavirin versus interferon ?-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425-432.
20. Thein H-H, Krahn M, Kaldor JM, et al. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100:643-651.
21. Stepanova M, Nader F, Cure S, et al. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014; 40:676-685.
22. Tapper EB, Sengupta N, Hunink MM, et al. Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol. 2015;110:1298-1304.
23. Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with directacting antivirals. Pharmacoeconomics. 2016;34:551-567.
24. Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397-406.
25. Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 2016:65-73.
26. Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol. 2016; 65:17-25.
27. Younossi Z, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41:544-563.
28. Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvirbased regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015;162:619-629.
29. Cortesi P, Mantovani L, Ciaccio A, et al. Cost-effectiveness of new directacting antivirals to prevent post-liver transplant recurrent hepatitis. Am J Transplant. 2015;15:1817-1826.
30. Saab S, Gonzalez YS, Huber C, et al. Cost-effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir + ribavirin for US post-liver transplant recurrent genotype 1 HCV. Liver Int. 2016;36:515-521.
31. Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. [published online ahead of print November 5, 2016]. Hepatology. DOI: 10.1002/hep.28926.